找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Cardiac Management of Oncology Patients; Clinical Handbook fo Gonzalo Baron Esquivias,Riccardo Asteggiano Book 2015 Springer International

[復(fù)制鏈接]
查看: 25328|回復(fù): 40
樓主
發(fā)表于 2025-3-21 17:27:19 | 只看該作者 |倒序瀏覽 |閱讀模式
書目名稱Cardiac Management of Oncology Patients
副標(biāo)題Clinical Handbook fo
編輯Gonzalo Baron Esquivias,Riccardo Asteggiano
視頻videohttp://file.papertrans.cn/222/221789/221789.mp4
概述Practical, rapid-reference pocketbook to assist physicians in managing oncology patients in the cardiology clinic.Thorough clinical review of the issues.Contains tips and tricks to assist patient’s ma
圖書封面Titlebook: Cardiac Management of Oncology Patients; Clinical Handbook fo Gonzalo Baron Esquivias,Riccardo Asteggiano Book 2015 Springer International
描述This book is designed for clinical cardiologists and other physicians working with cardiac patients, where specific specialized teams of cardio-oncologists are not available and who are called to perform a clinical consultation to evaluate both the cardiac condition and the eligibility for chemotherapy or radiotherapy treatment, and to evaluate if a cancer treatment produces toxic effects on a patient treated with chemo or radiotherapy and if appearance of new symptoms is due to this treatment. In recent years, progress in oncologic therapy has resulted in important developments and the prognostic improvement of patients with malignancy. The cornerstone of chemotherapy are the anthracyclines (and the analogue Mitoxantrone), that are direct cellular toxic agents and that are among the most powerful anti-neoplastic drugs, but their cardiac toxicity is well known. Significant breakthroughs in cancer therapy have also been achieved with the introduction of signalling inhibitors, such as VEGF inhibitors, HERB2 inhibitors or TK inhibitors used alone or in combination with direct cellular toxic drugs. However, these signalling inhibitors may interact also with cardiovascular signalling an
出版日期Book 2015
關(guān)鍵詞Anthracyclines; Cardio-Oncology; Cardiotoxicity; Chemotherapy; Radiotherapy; Radiaton Oncology
版次1
doihttps://doi.org/10.1007/978-3-319-15808-2
isbn_softcover978-3-319-15807-5
isbn_ebook978-3-319-15808-2
copyrightSpringer International Publishing Switzerland 2015
The information of publication is updating

書目名稱Cardiac Management of Oncology Patients影響因子(影響力)




書目名稱Cardiac Management of Oncology Patients影響因子(影響力)學(xué)科排名




書目名稱Cardiac Management of Oncology Patients網(wǎng)絡(luò)公開度




書目名稱Cardiac Management of Oncology Patients網(wǎng)絡(luò)公開度學(xué)科排名




書目名稱Cardiac Management of Oncology Patients被引頻次




書目名稱Cardiac Management of Oncology Patients被引頻次學(xué)科排名




書目名稱Cardiac Management of Oncology Patients年度引用




書目名稱Cardiac Management of Oncology Patients年度引用學(xué)科排名




書目名稱Cardiac Management of Oncology Patients讀者反饋




書目名稱Cardiac Management of Oncology Patients讀者反饋學(xué)科排名




單選投票, 共有 1 人參與投票
 

0票 0.00%

Perfect with Aesthetics

 

1票 100.00%

Better Implies Difficulty

 

0票 0.00%

Good and Satisfactory

 

0票 0.00%

Adverse Performance

 

0票 0.00%

Disdainful Garbage

您所在的用戶組沒有投票權(quán)限
沙發(fā)
發(fā)表于 2025-3-21 23:47:34 | 只看該作者
Physiopathology and Toxic Heart Effects of Chemotherapy Drugs,ardiac conditions, genetic pattern, and age and can manifest itself immediately or many years after. Concomitant treatments and radiotherapy can interfere with toxicity. Irreversible cytotoxicity (type I agents) or interaction with functional aspects of cardiac cells not primarily cytotoxic (type II
板凳
發(fā)表于 2025-3-22 04:26:01 | 只看該作者
地板
發(fā)表于 2025-3-22 06:22:49 | 只看該作者
5#
發(fā)表于 2025-3-22 12:28:35 | 只看該作者
6#
發(fā)表于 2025-3-22 14:38:55 | 只看該作者
Specific Clinic Problems in Cancer Therapy Cardiac Toxicity Complications,re, acute coronary syndrome, arrhythmias, and hypertension..Late cardiovascular effects are the most important complications and may include cardiomyopathy with or without congestive heart failure, arrhythmias, hypertension, ischemia, and pericardial disease. Cardiac dysfunction can be due to severa
7#
發(fā)表于 2025-3-22 17:02:39 | 只看該作者
8#
發(fā)表于 2025-3-23 00:33:07 | 只看該作者
Synthetic Tables,What drug/what possible complication
9#
發(fā)表于 2025-3-23 01:53:25 | 只看該作者
10#
發(fā)表于 2025-3-23 05:33:05 | 只看該作者
978-3-319-15807-5Springer International Publishing Switzerland 2015
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-18 13:14
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
皮山县| 六安市| 新蔡县| 忻城县| 扎鲁特旗| 章丘市| 邓州市| 大厂| 安化县| 茂名市| 玉环县| 七台河市| 瓮安县| 克东县| 广州市| 开阳县| 宾阳县| 乌拉特中旗| 巴东县| 揭阳市| 蒙山县| 易门县| 胶南市| 霍山县| 金山区| 南康市| 盐边县| 沾益县| 和林格尔县| 瑞金市| 嘉义市| 壶关县| 深水埗区| 怀安县| 同心县| 大埔县| 潼关县| 上林县| 晋州市| 重庆市| 庆元县|